Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Small Cell Lung Carcinoma/drug therapy"'
Autor:
Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael Schumacher, Elizabeth Dudnik, Michael Studnicka, Ronny Öhman, Robert Wurm, Luciano Wannesson, Nir Peled, Waleed Kian, Jair Bar, Sameh Daher, Alfredo Addeo, Ofer Rotem, Georg Pall, Alona Zer, Akram Saad, Tanja Cufer, Hadas Gantz Sorotsky, Sayed M. S. Hashemi, Katja Mohorcic, Ronen Stoff, Yulia Rovitsky, Shoshana Keren-Rosenberg, Thomas Winder, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair
Publikováno v:
Therapeutic Advances in Medical Oncology, 14. SAGE Publications Inc.
Therapeutic advances in medical oncology, vol. 14, pp. 1-22, 2022.
Illini, O, Fabikan, H, Swalduz, A, Vikström, A, Krenbek, D, Schumacher, M, Dudnik, E, Studnicka, M, Öhman, R, Wurm, R, Wannesson, L, Peled, N, Kian, W, Bar, J, Daher, S, Addeo, A, Rotem, O, Pall, G, Zer, A, Saad, A, Cufer, T, Sorotsky, H G, Hashemi, S M S, Mohorcic, K, Stoff, R, Rovitsky, Y, Keren-Rosenberg, S, Winder, T, Weinlinger, C, Valipour, A & Hochmair, M J 2022, ' Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program ', Therapeutic Advances in Medical Oncology, vol. 14 . https://doi.org/10.1177/17588359221103206, https://doi.org/10.1177/17588359221103206
Therapeutic advances in medical oncology, vol. 14, pp. 1-22, 2022.
Illini, O, Fabikan, H, Swalduz, A, Vikström, A, Krenbek, D, Schumacher, M, Dudnik, E, Studnicka, M, Öhman, R, Wurm, R, Wannesson, L, Peled, N, Kian, W, Bar, J, Daher, S, Addeo, A, Rotem, O, Pall, G, Zer, A, Saad, A, Cufer, T, Sorotsky, H G, Hashemi, S M S, Mohorcic, K, Stoff, R, Rovitsky, Y, Keren-Rosenberg, S, Winder, T, Weinlinger, C, Valipour, A & Hochmair, M J 2022, ' Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP) : a retrospective analysis from an early access program ', Therapeutic Advances in Medical Oncology, vol. 14 . https://doi.org/10.1177/17588359221103206, https://doi.org/10.1177/17588359221103206
Background: Patients with non-small cell lung cancer (NSCLC) presenting with mesenchymal–epithelial transition ( MET) exon 14 skipping mutation have an unfavorable prognosis with standard treatments. Capmatinib is a selective MET inhibitor, which s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db862aef7575b35683811d5d7626aa21
https://research.vumc.nl/en/publications/592f783c-ba18-49d9-bc6f-f98cf8baa811
https://research.vumc.nl/en/publications/592f783c-ba18-49d9-bc6f-f98cf8baa811
Autor:
Abdelhamid, K., Kakourou, A., Degrauwe, N., Nikolopoulou, A., Bouchaab, H., Peters, S., Nguyen-Ngoc, T., Mederos, N.
Publikováno v:
Revue medicale suisse, vol. 16, no. 695, pp. 1079-1085
Small cell lung cancer is a recalcitrant malignancy with 5-year survival rates of less than 20%. In the majority of cases, patients have metastatic disease at diagnosis despite the new screening method by low-dose CT-scan. The high throughput sequenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1900::99e447f6531b1546302cce451bb5834a
https://serval.unil.ch/notice/serval:BIB_3F2FC3093CB5
https://serval.unil.ch/notice/serval:BIB_3F2FC3093CB5
Autor:
Maria E. Riveiro, Mohamed Bekradda, Eric Raymond, Esteban Cvitkovic, Kay Noel, Lucile Astorgues-Xerri, Giorgio Inghirami, Keyvan Rezai, Maurizio D'Incalci, Francesco Bertoni, Ramiro Vázquez, Ivo Kwee, Andrea Rinaldi, Elodie Odore, Roberta Frapolli
Publikováno v:
Oncotarget, vol. 7, no. 51, pp. 84675-84687
Oncotarget
Oncotarget
// Maria E. Riveiro 1 , Lucile Astorgues-Xerri 1 , Ramiro Vazquez 2 , Roberta Frapolli 2 , Ivo Kwee 3, 5 , Andrea Rinaldi 3 , Elodie Odore 6 , Keyvan Rezai 6 , Mohamed Bekradda 1 , Giorgio Inghirami 7, 9 , Maurizio D’Incalci 2 , Kay Noel 10 , Esteb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3baf689a029b4ea760bd7e7c1a28109c
https://doi.org/10.18632/oncotarget.13181
https://doi.org/10.18632/oncotarget.13181
Autor:
Michaël Duruisseaux, Florian Huemer, Hannah Fabikan, Jeffrey Rothenstein, Malinda Itchins, Massimo Di Maio, Adrianus J. de Langen, Georg Pall, Florian Krenn, Katja Mohorcic, Alfredo Addeo, Gerald W. Prager, Christoph Weinlinger, Arschang Valipour, Okko-Sakari Kääränien, E. Laack, Stephen Clarke, Kristina Lamberg, Gudrun Absenger, Antonio Passaro, Antonio Calles, Ewald Wöll, Anders Vikström, Maximilian Hochmair, Oliver Illini, Alice Durand, Aurélie Swalduz, Achim Rittmeyer, Amanda Tufman, Shantanu Banerji, Michael Schumacher, Sayed M.S. Hashemi, Martin Wermke
Publikováno v:
Illini, O, Hochmair, M J, Fabikan, H, Weinlinger, C, Tufman, A, Swalduz, A, Lamberg, K, Hashemi, S M S, Huemer, F, Vikström, A, Wermke, M, Absenger, G, Addeo, A, Banerji, S, Calles, A, Clarke, S, di Maio, M, Durand, A, Duruisseaux, M, Itchins, M, Kääränien, O-S, Krenn, F, Laack, E, de Langen, A J, Mohorcic, K, Pall, G, Passaro, A, Prager, G, Rittmeyer, A, Rothenstein, J, Schumacher, M, Wöll, E & Valipour, A 2021, ' Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program ', Therapeutic Advances in Medical Oncology, vol. 13 . https://doi.org/10.1177/17588359211019675
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, 13. SAGE Publications Inc.
Therapeutic Advances in Medical Oncology
Therapeutic advances in medical oncology, vol. 13, pp. 1-17, 2021.
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, 13. SAGE Publications Inc.
Therapeutic Advances in Medical Oncology
Therapeutic advances in medical oncology, vol. 13, pp. 1-17, 2021.
Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccb6b16aa3c3964be405e128fd323706
https://doi.org/10.1177/17588359211019675
https://doi.org/10.1177/17588359211019675
Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer
Autor:
Sheryl Roberts, Susanne Kossatz, Christian Brand, M. Jason de la Cruz, Willem J. M. Mulder, Junior Gonzales, Thomas Reiner, Giacomo Pirovano, Patrick L. Donabedian, Carlos Pérez-Medina
Publikováno v:
Bioconjugate Chemistry, 29(11), 3776-3782. American Chemical Society
Bioconjugate chemistry, 29(11), 3776-3782. American Chemical Society
Bioconjugate chemistry, 29(11), 3776-3782. American Chemical Society
The preclinical potential of many diagnostic and therapeutic small molecules is limited by their rapid washout kinetics and consequently modest pharmacological performances. In several cases, these could be improved by loading the small molecules int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4a32309149150e80d69849105b78ad1
https://europepmc.org/articles/PMC6548450/
https://europepmc.org/articles/PMC6548450/
Autor:
Fabio Gomes, Fiona H Blackhall, Kristopher K. Frese, Katie Baker, Martin Forster, Maximilian W Schenk, Alice Lallo, Victoria Foy, Caroline Dive
Publikováno v:
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Foy, V, Schenk, M, Baker, K, Gomes, F, Lallo, A, Frese, K, Forster, M, Dive, C & Blackhall, F 2017, ' Targeting DNA damage in SCLC ', Lung Cancer, vol. 114, 11, pp. 12-22 . https://doi.org/10.1016/j.lungcan.2017.10.006
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP
Foy, V, Schenk, M, Baker, K, Gomes, F, Lallo, A, Frese, K, Forster, M, Dive, C & Blackhall, F 2017, ' Targeting DNA damage in SCLC ', Lung Cancer, vol. 114, 11, pp. 12-22 . https://doi.org/10.1016/j.lungcan.2017.10.006
SCLC accounts for 15% of lung cancer worldwide. Characterised by early dissemination and rapid development of chemo-resistant disease, less than 5% of patients survive 5 years. Despite 3 decades of clinical trials there has been no change to the stan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2d985075e4d708fa0a6f83fb0013005
https://hdl.handle.net/10400.17/2823
https://hdl.handle.net/10400.17/2823
Publikováno v:
Medical Oncology, Vol. 26, No 3 (2009) pp. 298-302
The aim of the study is to evaluate the outcome of low-dose bifractionated up-front radiotherapy (RT) followed by chemotherapy (CHT) in limited-disease small cell lung cancer (LD-SCLC). From December 1999 to February 2002, 20 LD-SCLC consecutive pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fcd59381c864f9a15aa28df66b2b4b3
https://pubmed.ncbi.nlm.nih.gov/19002616
https://pubmed.ncbi.nlm.nih.gov/19002616
Autor:
Roberta Ferraldeschi, Paul Lorigan
Publikováno v:
Ferraldeschi, R & Lorigan, P 2009, ' Extensive-stage small-cell lung cancer—moving beyond response rate? ', Annals of Oncology, vol. 20, no. 5, pp. 801-802 . https://doi.org/10.1093/annonc/mdp247
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5fad15b216c72e34cbd60ce8db40b05
https://doi.org/10.1093/annonc/mdp247
https://doi.org/10.1093/annonc/mdp247
Autor:
Curzio Rüegg, Solange Peters
Publikováno v:
Journal of the National Cancer Institute, vol. 101, no. 15, pp. 1034-1035
Keywords: Phase-Ii Trial ; Maintenance Therapy ; Tumor Angiogenesis ; Multiple-Myeloma ; Double-Blind ; Chemotherapy ; Growth Reference EPFL-ARTICLE-159544doi:10.1093/jnci/djp208View record in Web of Science Record created on 2010-11-30, modified on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc462ed36719c683a6c074d094437dc7
https://infoscience.epfl.ch/record/159544
https://infoscience.epfl.ch/record/159544
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.